---
title: "EPIRUS Therapeutics: Buy Rating Reiterated on EP-104GI’s Emerging Clinical Profile and Upcoming Phase 2b Catalyst; $16 Price Target Unchanged"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300606261.md"
description: "LifeSci Capital analyst Sam Slutsky reiterated a Buy rating on Eupraxia Pharmaceuticals (EPRX) with an unchanged $16 price target. The recommendation is driven by EP-104GI’s promising Phase 1b/2a RESOLVE data in eosinophilic esophagitis, showing durable symptom relief and histologic response. Despite small cohort limitations, consistent improvements support the drug's potential as a once-yearly therapy. Combined with a two-year cash runway and upcoming Phase 2b catalysts, the risk-reward profile justifies the favorable outlook."
datetime: "2026-09-30T17:55:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300606261.md)
  - [en](https://longbridge.com/en/news/300606261.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300606261.md)
generator: "portal-rs"
---

# EPIRUS Therapeutics: Buy Rating Reiterated on EP-104GI’s Emerging Clinical Profile and Upcoming Phase 2b Catalyst; $16 Price Target Unchanged

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Eupraxia Pharmaceuticals today and set a price target of $16.00.

Sam Slutsky has given his Buy rating due to a combination of factors tied to EP-104GI’s emerging clinical profile and the upcoming Phase 2b data readout. The updated Phase 1b/2a RESOLVE results in eosinophilic esophagitis show durable symptom relief and histologic response, particularly in higher-dose cohorts, reinforcing the potential for EP-104GI as a once-yearly, long-acting therapy that could differentiate meaningfully in a disease with limited treatment options.

While acknowledging the limitations of small, open-label cohorts, Slutsky views the consistency of Straumann Dysphagia Index improvements and sustained clinical remission rates over 36–52 weeks as supportive of the program’s risk-reward profile. Combined with a roughly two-year cash runway, current valuation, and an unchanged $16 price target, he believes the near-term Phase 2b catalyst and long-term commercial opportunity justify a favorable risk-adjusted outlook, underpinning his Buy recommendation on EPRX.

### Related Stocks

- [EPRX.US](https://longbridge.com/en/quote/EPRX.US.md)

## Related News & Research

- [Eupraxia says EP-104GI keeps 64% of EoE patients in remission at 52 weeks in RESOLVE trial data](https://longbridge.com/en/news/300568655.md)
- [HC Wainwright & Co. reiterates Buy rating on Eupraxia Pharmaceuticals, $11 price target](https://longbridge.com/en/news/300671439.md)
- [Rocket Lab or Palantir: Cathie Wood Buys $16.4M of One Stock, Sells $4M of the Other](https://longbridge.com/en/news/300746214.md)
- [Google Stock Gets $420 Price Target from BNP Paribas – Here's Why](https://longbridge.com/en/news/300731266.md)
- [Why Did Google Stock Gain in After-Hours Trading on Wednesday?](https://longbridge.com/en/news/300646068.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**